Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2015. The document serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific transaction notification and does not contain comprehensive financial statements.
Material Changes
The filing reports a specific increase in the notional allocation of GSK American Depositary Shares (ADSs) on September 25, 2015. This change resulted from the revaluation of the cash element of a notional investment held within the GSK 401K plan. The transaction occurred at a price of $38.48 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction disclosed.
Key Facts for Investor Verification
- Transaction Date: September 25, 2015 (Notified September 28, 2015).
- Connected Person: Dr K Slaoui (Connected Person of Dr M Slaoui).
- Transaction Type: Increase in notional allocation of ADSs within the GSK 401K plan.
- Quantity: 9 ADSs.
- Price: $38.48 per ADS.
- Signatory: Victoria Whyte, Company Secretary.